Paul Edwards MBE
Executive Chair at IsomAb Ltd
Bridgeen Callan
CEO of klas therapeutics
Rob Chisholm
CEO of ReForm Therapeutics Ltd
Tom Congdon
CEO of CryoLogyx Ltd
Dave Cook
CEO of Quodria Ltd
Nicky Cooper
CEO of River BioMedics
Alastair Corbin
Principal Scientist at Molecule to Medicine
Clare Doris
Exec Chair/Acting CEO of GIO Therapeutics AG
Johan Faber
CEO of Cymab APS
Waleed Faisal
CEO of ArrayPatch Ltd
Torbjørn Furuseth
CEO and Co-Founder of DoMore DiagnosticsWe personalize cancer treatment with digital biomarkers trained with AI to analyze routine tumor histology slides. This is a segment of diagnostics with multi-gene tests priced at USD 4000. Colorectal cancer is our lead indication, a USD 700m market that we can reach with low investments and in short time.
Kenji Hashimoto
Founder of Bi-Path Bio, Ltd
Emma Hayhurst
CEO of Llusern Scientific
Alistair Irvine
CEO of Scarlet TherapeuticsAlistair Irvine, PhD, joined Scarlet as CEO in August 2022. He is an experienced biotech and medtech executive who has worked in the industry for >28 years and has broad international executive and R&D experience. Previous to Scarlet, he was Chief Business Officer at Kuros Biosciences AG, a public Swiss biotech company, and he has also held senior management roles at Innovata plc, ML Laboratories plc, and Cobra Therapeutics Ltd. Dr. Irvine holds a PhD in Molecular Biology from the University of Sheffield, U.K. and a BSc in biochemistry from the University of Edinburgh, U.K.
Agnieszka Janeczek
CEO of Renovos Biologics Limited
Karen Kempsell
Senior Scientist at UKHSA
Thomas Kirk
CEO of Quantified Imaging
Dominique Kleyn
Cofounder and COO of Orthonika LimitedDominique's focus at Orthonika is directing business development and operations, playing a key role in strategic planning, fundraising, intellectual property management and licensing. She has experience in both industrial and academic sectors with collaborators in UK and overseas.
Tiina Kähkönen
Chief Scientific Officer at OncoBone Therapeutics Ltd
Ryan Lafferty
Chief Executive Officer at Dia Beta Labs Ltd
Liza Levy
Co-founder of Unravel Health
Ramsay McFarlane
Doctor / CEO of Awen Oncology Limited
Robert Miller
Chief Medical Officer at Hubro Bioscience
Massimo Mineo
CEO of Neurolieve Biosciences
Lasse Nørregaard
CBO at Loma Therapeutics
Olaf Piepenburg
Managing Director of PartitionBio
Alice Preston
Co-Founder CEO of Panthura
Kate Rowley
CEO of Assemblify
Fiona Rudkin
CEO of mycoBiologics LtdFrancesco Sergi-Lindell
CEO of PreTT ApS
Nick Sireau
CEO and Co-founder of Serenatis Bio
Rory Triniman
CEO of Veirulence Ltd
Auke Van Heel
PhD / CEO of Omnicin Therapeutics
Simon Walker
CEO of MicrosensDx LimitedJonathan Ward
CEO of THERAtRAME SA
Francis White
CEO of Heart Biotech Ltd
Toby Wilson Waterworth
CEO of Ambrose HealthcareAmbrose Healthcare is a specialist rare disease pharmaceutical company, developing a late stage portfolio of new solutions and treatments for rare diseases, quickly and cost effectively. Ambrose has an experienced pharmaceutical team, supported by an international network of rare disease experts and organisations, including digital tools and AI.
Sam Windsor
CEO of Ignota LabsIgnota Labs is the world’s first AI-native pharmaceutical asset turnaround company, identifying and revitalising undervalued assets with safety concerns. Our AI-native turnaround approach integrates Large Language Models, bioinformatics and cheminformatics, enabling us to uniquely identify and salvage the golden opportunities from thousands of clinical and preclinical failures every year.